* Hikma, which bought Boehringer Ingelheim's U.S. genericdrugs business this year, said it now expected full-year revenuefrom the business to be $600 million (482 million pounds), downfrom $640 million-$670 million it expected in August. * The company said in August that it expected full-year coreoperating profit from its generics unit to be hurt by a delay inapproval of new products and higher-than-expected costs. * Hikma said it expected full-year group revenue to grow 35percent to around $2 billion in constant currency. It hadpreviously forecast revenue of $2.0-$2.10 billion in August.

(Reporting by Pranav Kiran in Bengaluru; Editing by Sunil Nair)